In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies by Aimee E. Mattei, Andres H. Gutierrez, Soorya Seshadri, Jacob Tivin, Matt Ardito, Amy S. Rosenberg, William D. Martin, Anne S. De Groot

Subjects: “…Anti-drug antibodies…”
Get full text

Gastroprotective effects of the isopropanol extract of Artemisia princeps and its gastroretentive floating tablets on gastric mucosal injury by Kim Joo-Il, Park Sang-Wook, Lim Jhong-Jae, Sohn Se-Il, Shin Ji-Su, Park Sang Cheol, Jang Young Pyo, Chung Eun Kyoung, Lee Hong-Woo, Lee Kyung-Tae

Subjects: Get full text

Safety of palliative cancer patients using morphine for pain control: scoping review by Janillê Luciana Araújo, Erica Brandão de Moraes, Barbara Pompeu Chistovam, Aline Lima Pestana Magalhães

Subjects: Get full text

Therapeutic Levels of Acetaminophen Causing AKI: A Case Report and Literature Review by Hamnah Tayyab, Lavanya Dhondapati, Ashraf Ullah, Mohammed Dheyaa Marsool Marsool, Singh Jagmeet, Khabab Abbasher Hussien Mohamed Ahmed

Subjects: Get full text

Determinants of nosocomial infections and emerging antibiotic resistance in the Intensive Care Unit: A prospective evidence-based study by Pranali Patil, Amol Muthal, Jignesh Shah, Asavari Raut

Subjects: Get full text

Determination of Acetyl Salicylic Acid in Aspirin tablets by Lana Mohammed Ali, Mariwan Abdulla Hama Salih, Omed Ismael Hayder

Subjects: “…Drug analysis, HPLC, Titration, Back-Titration, Aspirin, Spectrophotometer, Acetyl Salicylic Acid.…”
Get full text

Epidemiological Characteristics and Prognostic Scoring in Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome: Insights from a 17-Year Burn Center Experience by David Breidung, Sarina Delavari, Ioannis-Fivos Megas, Alexander Geierlehner, Wolfgang Hitzl, Karl J. Bodenschatz, Konrad Karcz, Denis Ehrl, Moritz Billner

Subjects: Get full text

Pituitary adenylate cyclase-activating polypeptide plays a role in neuropsychiatric and substance use disorders: sex-specific perspective by Catherine E. Van Doorn, Mikala M. Zelows, Anel A. Jaramillo

Subjects: Get full text

Editorial: Advancements in equine pain management by Ludovica Chiavaccini, Rachel Anne Reed, Claudia Spadavecchia

Subjects: Get full text

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020 by M.L. Rekart, P. Thit, M. Oluya, S. Moe, T. Hasan, N. Parpieva, K. Safaev, A. Khristusev, T. Zinaida, J. Singh, S. Allamuratova, I. Azamat, C.G. Restrepo, N. Sitali, J. Achar, J.L. Alvaraez, A. Sinha

Subjects: Get full text

Insights Into Antimicrobial Resistance From Dental Students in the Asia–Pacific Region by Saba Ghafoor, Gabriela Salvadori, Shiho Kino, Vy Thi Nhat Nguyen, Tam Thi-Thanh Nguyen, Miho Ishimaru, Antônio Pedro Ricomini-Filho, Cassiano Kuchenbecker Rösing, Dileep De Silva, Jun Aida, Belinda Farias Nicolau, Ratilal Lalloo, Roger Junges

Subjects: Get full text

Dual targeting carbonic anhydrase inhibitors as promising therapeutic approach: a structural overview by Katia D’Ambrosio, Anna Di Fiore, Emma Langella

Subjects: Get full text

Heart-on-a-chip: a revolutionary organ-on-chip platform for cardiovascular disease modeling by Beiqin Liu, Shuyue Wang, Hong Ma, Yulin Deng, Jichen Du, Yimeng Zhao, Yu Chen

Subjects: Get full text

Antimicrobial resistance and epidemiological patterns of Streptococcus pyogenes in Türkiye by Nihan Ünübol, Nese Caglayan, Sinan Cebeci, Yeşim Beşli, Banu Sancak, Neval Yurttutan Uyar, Siavosh Salmanzadeh Ahrabi, Masoud Alebouyeh, Tanıl Kocagöz

Subjects: Get full text

Assessment of different genotyping markers and algorithms for distinguishing Plasmodium falciparum recrudescence from reinfection in Uganda. by Mwesigwa, Alex, Golumbeanu, Monica, Jones, Sam, Cantoreggi, L. Sara, Musinguzi, Benson, Nankabirwa, I. Joaniter, Bikaitwoha, Everd Maniple, Kalyango, N. Joan, Karamagi, Charles, Plucinski, Mateusz, Nsobya, L. Samuel, Nsanzabana, Christian, Byakika-Kibwika, Pauline

Subjects: Get full text

A single-site randomized controlled trial of partner navigation to HCV treatment for people who inject drugs: a study protocol for the You’re Empowered for Treatment Initiation (YETI) partner trial by Meghan D. Morris, Judy Y. Tan, Claire C. McDonell, Maia Scarpetta, Tiffany N. Nguyen, Jennifer C. Price, Torsten B. Neilands

Subjects: Get full text

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma by Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani

Get full text

Navigating DR-TB Treatment care: a qualitative exploration of barriers and facilitators to retention in care among people with history of early disengagement from drug-resistant tuberculosis treatment in Johannesburg, South Africa by Ndiviwe Mphothulo, Sindisiwe Hlangu, Jennifer Furin, Mosa Moshabela, Marian Loveday

“…Abstract Background Despite advances in drug-resistant tuberculosis (DR-TB) diagnosis, treatment, and service delivery, individuals with DR-TB often face significant socioeconomic and psychosocial challenges due to limited resources. …”
Get full text

Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study by Hao-Yu Wang, Yang Wang, Dong Yin, Run-Lin Gao, Yue-Jin Yang, Bo Xu, Ke-Fei Dou

“…The relation between complex percutaneous coronary intervention (PCI), high bleeding risk (HBR), and adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterized. …”
Get full text

Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis by Christophe Cisarovsky, Marie Théaudin, Pierre-Alexandre Bart, Grégoire Stalder, Lorenzo Alberio

“…Interferon β-1a (IFNβ1a) is considered safe in relapsing-remitting multiple sclerosis (RRMS). Drug-induced thrombocytopenia (DITP) is a rare but underreported adverse event that is often confused with other causes of thrombocytopenia. …”
Get full text